The Readout Loud

View Top 200 Chart

Back to Rankings Page

Business
**The Readout Loud**

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Latest Episodes:

Episode 118: Remdesivir’s controversial cost, early vaccine promise, and AI at the end of life Jul 02, 2020

Show notes

What’s a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care?

Episode 117: Covid-19’s U.S. surge, GSK’s mystery whistleblower, and cancer care under coronavirus Jun 25, 2020

Show notes

Is this a second wave or a rising tide? Who’s the real GlaxoSmithKline whistleblower? And what happens to cancer care in a pandemic?

Episode 116: Ezekiel Emanuel on vaccine politics & Tshaka Cunningham on diversifying genetic testing Jun 18, 2020

Show notes

Can a vaccine be an October surprise? Are journal publishers running a racket? And why is genetics so white?

Episode 115: The Chan-Zuck uprising, a virtual BIO, and the struggle to treat Covid-19 Jun 11, 2020

Show notes

Can a virtual conference feel real? Do scientists have a say in their benefactors' business? And what does it take to get remdesivir in the U.S.?

Episode 114: The killing of George Floyd, the drug industry's response, and what comes next Jun 04, 2020

Show notes

The killing of George Floyd at the hands of a white Minneapolis police officer has brutally underlined the systemic racism that informs policing, housing, education, and health care in the U.S. This podcast covers the world of biotech, which, like every facet of our society, is affected by racism and inequality. So, first, we talk about how the drug industry has responded to Floyd’s killing and what that response means. Then, we're joined for a conversation with longtime biotech executive Tony Coles, who is also a founding member of the Black Economic Alliance, a group of business leaders who raise money for candidates and causes. We talk about why Floyd's killing sparked global action, the relative value of public statements, and what business leaders can do to combat racism.

Episode 113: Life after a coronavirus vaccine, virtual ASCO, and remembering Larry Kramer May 28, 2020

Show notes

What happens after we get a coronavirus vaccine? Can virtual medical meetings replace the real thing? And wasn’t Amazon supposed to disrupt health care?

Episode 112: Moderna's scant coronavirus data and the plight of the day trader May 21, 2020

Show notes

When is a press release worth $5 billion? Can biotech stocks replace sports? And how will we know if a coronavirus vaccine actually works?

Episode 111: Covid-19 in the White House, a Parkinson’s experiment & public health lessons from porn May 14, 2020

Show notes

What can the adult film industry teach us about fighting coronavirus? Does the FDA approve Zoom backgrounds? And is it ethical to fund a study of yourself?

Episode 110: Pandemic projections, Gilead's pricing dilemma & fighting Covid-19 in New York May 07, 2020

Show notes

What if the curve just stays flat? How much should a Covid-19 drug cost? And what's it like on the ground in the epicenter of the novel coronavirus?

Episode 109: Scott Gottlieb on Covid-19 treatments, reopening America, and going on TV every day Apr 30, 2020

Show notes

Just how well does Gilead Sciences' Covid-19 drug work? Is politics getting in the way of public health? And who gets the eventual coronavirus vaccine first?

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected